vTv Therapeutics Inc. Class A Common Stock (VTVT)

About VTVT

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

26

Website

vtvtherapeutics.com/

Fundamentals

1-day range

$34.46$36.51

Market cap

$136.33M

P/E (trailing)

55.59

P/E (forward)

-8.69

EPS (trailing)

$-0.92

Dividend yield

—

Beta

0.20

Avg. volume

70.3K

Forecasts

6 analyst ratings

vTv Therapeutics Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• VTVT

  vTv Therapeutics Inc. Class A Common Stock

  $32.17

  ▼ 1.92%
  Market cap $136.33MP/E 55.59
  $15.79$44
• CNTB

  Connect Biopharma Holdings Limited Ordinary Shares

  $2.22

  ▼ 2.63%
  Market cap $137.89MP/E —
  $1.23$3.82
• HURA

  TuHURA Biosciences Inc. Common Stock

  $2.11

  ▼ 1.17%
  Market cap $134.69MP/E —
  $0.41$3.43
• EQ

  Equillium Inc. Common Stock

  $2.39

  ▼ 2.65%
  Market cap $134.04MP/E —
  $0.76$3.54
• OGI

  Organigram Global Inc. Common Shares

  $1.22

  ▼ 0.81%
  Market cap $139.37MP/E 2.82
  $1.2$3.09
• KZIA

  Kazia Therapeutics Limited American Depositary Shares

  $13.59

  ▼ 19.59%
  Market cap $140.89MP/E —
  $4.86$17.4
• NGEN

  NervGen Pharma Corp. Common stock

  $2.27

  ▼ 2.78%
  Market cap $141.37MP/E —
  $3.2$8.49

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42
  benzinga · 8/6/2026
• HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42
  Benzinga · 8/6/2026
• vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate
  Benzinga · 8/6/2026

Institutional Ownership

March 31, 2026

Total shares held

1.47M

Total value held

$58.29M

Institutional holders

33